Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
UBE1L causes lung cancer growth suppression by targeting cyclin D1.
Feng Q, Sekula D, Guo Y, Liu X, Black CC, Galimberti F, Shah SJ, Sempere LF, Memoli V, Andersen JB, Hassel BA, Dragnev K, Dmitrovsky E. Feng Q, et al. Among authors: memoli v. Mol Cancer Ther. 2008 Dec;7(12):3780-8. doi: 10.1158/1535-7163.MCT-08-0753. Mol Cancer Ther. 2008. PMID: 19074853 Free PMC article.
Uncovering growth-suppressive MicroRNAs in lung cancer.
Liu X, Sempere LF, Galimberti F, Freemantle SJ, Black C, Dragnev KH, Ma Y, Fiering S, Memoli V, Li H, DiRenzo J, Korc M, Cole CN, Bak M, Kauppinen S, Dmitrovsky E. Liu X, et al. Among authors: memoli v. Clin Cancer Res. 2009 Feb 15;15(4):1177-83. doi: 10.1158/1078-0432.CCR-08-1355. Clin Cancer Res. 2009. PMID: 19228723 Free PMC article.
Evidence for the ubiquitin protease UBP43 as an antineoplastic target.
Guo Y, Chinyengetere F, Dolinko AV, Lopez-Aguiar A, Lu Y, Galimberti F, Ma T, Feng Q, Sekula D, Freemantle SJ, Andrew AS, Memoli V, Dmitrovsky E. Guo Y, et al. Among authors: memoli v. Mol Cancer Ther. 2012 Sep;11(9):1968-77. doi: 10.1158/1535-7163.MCT-12-0248. Epub 2012 Jul 2. Mol Cancer Ther. 2012. PMID: 22752428 Free PMC article.
Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer.
Ma T, Galimberti F, Erkmen CP, Memoli V, Chinyengetere F, Sempere L, Beumer JH, Anyang BN, Nugent W, Johnstone D, Tsongalis GJ, Kurie JM, Li H, Direnzo J, Guo Y, Freemantle SJ, Dragnev KH, Dmitrovsky E. Ma T, et al. Among authors: memoli v. Mol Cancer Ther. 2013 Aug;12(8):1545-55. doi: 10.1158/1535-7163.MCT-12-0933. Epub 2013 May 16. Mol Cancer Ther. 2013. PMID: 23686769 Free PMC article.
Bexarotene and erlotinib for aerodigestive tract cancer.
Dragnev KH, Petty WJ, Shah S, Biddle A, Desai NB, Memoli V, Rigas JR, Dmitrovsky E. Dragnev KH, et al. Among authors: memoli v. J Clin Oncol. 2005 Dec 1;23(34):8757-64. doi: 10.1200/JCO.2005.01.9521. J Clin Oncol. 2005. PMID: 16314636 Clinical Trial.
Uncovering novel targets for cancer chemoprevention.
Dragnev KH, Feng Q, Ma Y, Shah SJ, Black C, Memoli V, Nugent W, Rigas JR, Kitareewan S, Freemantle S, Dmitrovsky E. Dragnev KH, et al. Among authors: memoli v. Recent Results Cancer Res. 2007;174:235-43. doi: 10.1007/978-3-540-37696-5_21. Recent Results Cancer Res. 2007. PMID: 17302201 Review.
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.
Dragnev KH, Ma T, Cyrus J, Galimberti F, Memoli V, Busch AM, Tsongalis GJ, Seltzer M, Johnstone D, Erkmen CP, Nugent W, Rigas JR, Liu X, Freemantle SJ, Kurie JM, Waxman S, Dmitrovsky E. Dragnev KH, et al. Among authors: memoli v. Cancer Prev Res (Phila). 2011 Jun;4(6):818-28. doi: 10.1158/1940-6207.CAPR-10-0376. Cancer Prev Res (Phila). 2011. PMID: 21636548 Free PMC article. Clinical Trial.
179 results